File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma

TitleErlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma
Authors
Keywordsanimal experiment
animal model
animal tissue
cancer inhibition
cancer recurrence
Issue Date2020
PublisherNature Research (part of Springer Nature): Fully open access journals. The Journal's web site is located at http://www.nature.com/npjgenmed/
Citation
npj Genomic Medicine, 2020, v. 5, p. article no. 17 How to Cite?
AbstractHead and neck squamous cell carcinoma (HNSCC) lacks predictive biomarkers for drug responses. By targeted sequencing, we identified two MAPK1 mutations in recurrent HNSCC, MAPK1p.D321N, and p.R135K. We previously reported an exceptional erlotinib responder with MAPK1p.E322K. Here, by in silico and drug studies, we determined functions of these two recurrence-associated MAPK1 mutations. Residues D321, R135, and E322 are in 3D proximity. MAPK1p.D321N drives marked in vivo erlotinib sensitivity, while p.R135K’s effect is moderate.
Persistent Identifierhttp://hdl.handle.net/10722/290112
ISSN
2019 Impact Factor: 5.631
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorNgan, HL-
dc.contributor.authorPoon, PHY-
dc.contributor.authorSu, YX-
dc.contributor.authorChan, JYK-
dc.contributor.authorLo, KW-
dc.contributor.authorYeung, CK-
dc.contributor.authorLiu, Y-
dc.contributor.authorWong, E-
dc.contributor.authorLi, H-
dc.contributor.authorLau, CW-
dc.contributor.authorPiao, W-
dc.contributor.authorLui, VWY-
dc.date.accessioned2020-10-22T08:22:16Z-
dc.date.available2020-10-22T08:22:16Z-
dc.date.issued2020-
dc.identifier.citationnpj Genomic Medicine, 2020, v. 5, p. article no. 17-
dc.identifier.issn2056-7944-
dc.identifier.urihttp://hdl.handle.net/10722/290112-
dc.description.abstractHead and neck squamous cell carcinoma (HNSCC) lacks predictive biomarkers for drug responses. By targeted sequencing, we identified two MAPK1 mutations in recurrent HNSCC, MAPK1p.D321N, and p.R135K. We previously reported an exceptional erlotinib responder with MAPK1p.E322K. Here, by in silico and drug studies, we determined functions of these two recurrence-associated MAPK1 mutations. Residues D321, R135, and E322 are in 3D proximity. MAPK1p.D321N drives marked in vivo erlotinib sensitivity, while p.R135K’s effect is moderate.-
dc.languageeng-
dc.publisherNature Research (part of Springer Nature): Fully open access journals. The Journal's web site is located at http://www.nature.com/npjgenmed/-
dc.relation.ispartofnpj Genomic Medicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectanimal experiment-
dc.subjectanimal model-
dc.subjectanimal tissue-
dc.subjectcancer inhibition-
dc.subjectcancer recurrence-
dc.titleErlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma-
dc.typeArticle-
dc.identifier.emailSu, YX: richsu@hku.hk-
dc.identifier.authoritySu, YX=rp01916-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41525-020-0124-5-
dc.identifier.pmid32351709-
dc.identifier.pmcidPMC7171136-
dc.identifier.scopuseid_2-s2.0-85083970486-
dc.identifier.hkuros316522-
dc.identifier.volume5-
dc.identifier.spagearticle no. 17-
dc.identifier.epagearticle no. 17-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats